Skip to content
stoqly

Innospec

IOSP Nasdaq Specialty Chemicals Financials FY2016–FY2025

Innospec's revenue fell 3.6% to $1.8 billion in fiscal 2025. Its operating margin was 7.3%, down from 9.6% a year earlier. Free cash flow was $88 million, down 38.5%. It paid out $66 million in dividends and buybacks, 75% of free cash flow. The diluted share count fell 0.5%.

Last close · Oct 23, 2026

$98.64

0.0%
Value it Compare
Revenue Total sales reported in the income statement.
$1.8B
3.7% vs prior year
Operating margin Operating income as a share of revenue.
7.3%
2.4 pts
Net income Profit after all expenses, interest and tax.
$117M
227.5%
Free cash flow Cash from operations minus capital spending.
$88.0M
38.5%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
11.1%
5.3 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$2.4B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
20.1x
On $4.90 EPS (TTM)

What Innospec does

No business description yet.

Legal name
INNOSPEC INC.
Fiscal year ends
December 31, 2025
Latest annual report
—
Accession · CIK
0001193125-26-056502
0001054905

Revenue and margins

Innospec had $1.8B of revenue in fiscal 2025, down 3.7% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

From fiscal 2016 to 2025, diluted EPS grew 3.8% a year. Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $88.0M in fiscal 2025, 5.0% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Innospec returned $66.3M to shareholders in fiscal 2025, 75% of free cash flow. The diluted share count fell 0.5%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Innospec yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of $293M and divides by 25.0M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 20.1x · peers 31.8x · sector 20.6x.

Balance sheet

Cash, debt and the ratios that show how comfortably Innospec can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $142M$147M$204M$289M$293M
Debt incl. finance leases $0.1M$0.0M$0.0M$0.0M$0.0M
Net debt / EBITDA −0.8x−0.7x−1.0x−1.3x−1.7x
Debt / equity 0.0x0.0x0.0x0.0x0.0x
Current ratio 2.2x2.2x2.4x2.6x2.8x
Quick ratio 1.3x1.2x1.6x1.8x1.9x
Total assets $1.6B$1.6B$1.7B$1.7B$1.8B
Total liabilities $538M$563M$558M$519M$500M
Shareholders' equity $1.0B$1.0B$1.1B$1.2B$1.3B
Net debt (− = net cash) −$142M−$147M−$204M−$289M−$293M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

1 insider

Sold, 12 months

$0.4M

5 insiders

Of sales under plans

0%

$0.0M

DateInsiderTradeSharesPriceValueFiling
Mar 3, 2026 David B. JonesSVP, GC & CCO Sold 1,028 $75.64 $0.1M Form 4
Feb 27, 2026 Claudia PocciaDirector Sold 119 $76.56 $0.0M Form 4
Feb 27, 2026 David LandlessDirector Sold 594 $76.56 $0.0M Form 4
Feb 27, 2026 Ian CleminsonEVP & CFO Sold 2,380 $76.56 $0.2M Form 4
Feb 20, 2026 Larry PADFIELDDirector Sold 1,030 $81.84 $0.1M Form 4
Nov 14, 2025 Leslie J ParretteDirector Bought 340 $74.09 $0.0M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✓ ✓ ✓
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✓ ✕ ✓
Cash from operations exceeds net income ✓ ✓ ✓
Debt fell relative to assets ✕ ✕ ✕
Current ratio rose ✓ ✓ ✓
Share count didn't rise ✕ ✕ ✓
Gross margin rose ✓ ✕ ✕
Revenue rose relative to assets ✕ ✕ ✕
F-score 6 / 94 / 96 / 9
Accruals ratio −4.1%−8.7%−1.2%
Altman Z'' 6.747.297.54

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Innospec IOSP $2.4B −3.7% 7.3% 5.0% 11.1% 20.1x 6
Quaker Chemical KWR $2.7B 2.7% 2.8% 4.3% 1.3% 27.8x 5 Compare →
Sensient Technologies SXT $5.7B 3.5% 12.9% 2.4% 8.9% 35.8x 6 Compare →
Minerals Technologies MTX $2.0B −2.2% 2.3% 4.2% 1.6% — 4 Compare →
Stepan SCL $1.5B 7.0% 3.4% 1.1% 3.6% — 6 Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $883M $1.3B $1.5B $1.5B $1.2B $1.5B $2.0B $1.9B $1.8B $1.8B
Gross profit $332M $403M $435M $466M $343M $435M $587M $591M $543M $492M
Research and development $25.4M $31.4M $33.4M $35.4M $30.9M $37.4M $38.7M $49.0M $56.5M $51.0M
Operating income $98.2M $125M $134M $150M $33.7M $132M $187M $162M $178M $130M
Interest expense $2.6M $7.2M $6.5M $4.8M $0.8M $0.0M $0.0M $0.0M $0.0M $0.0M
Pretax income $103M $128M $132M $150M $39.7M $134M $185M $174M $41.2M $138M
Income tax $21.8M $66.3M $46.6M $38.2M $11.0M $41.3M $51.6M $35.3M $5.6M $21.5M
Net income $81.3M $61.8M $85.0M $112M $28.7M $93.1M $133M $139M $35.6M $117M
Diluted EPS $3.33 $2.52 $3.45 $4.54 $1.16 $3.75 $5.32 $5.56 $1.42 $4.67
Diluted shares 0.02B 0.02B 0.02B 0.02B 0.02B 0.02B 0.03B 0.03B 0.03B 0.03B
Cash flow
Cash from operations $106M $82.7M $105M $162M $146M $93.2M $81.7M $207M $185M $138M
Capital expenditure $16.5M $23.3M $28.9M $29.9M $29.7M $39.1M $39.6M $62.1M $41.4M $50.3M
Free cash flow $89.0M $59.4M $76.0M $132M $116M $54.1M $42.1M $145M $143M $88.0M
Depreciation and amortization $38.1M $50.4M $49.6M $47.6M $46.0M $42.7M $40.1M $39.3M $43.5M $43.6M
Stock-based compensation $3.3M $4.1M $4.9M $6.6M $5.8M $4.4M $6.7M $8.0M $8.5M $8.1M
Acquisitions $197M $2.6M $5.4M $0.0M $0.0M $0.0M $0.0M $34.7M $0.2M $0.7M
Share buybacks $8.4M $1.1M $1.4M $2.4M $2.1M $0.8M $5.9M $1.1M $0.7M $23.9M
Dividends paid $15.9M $18.6M $21.7M $25.0M $25.6M $28.8M $31.7M $35.1M $38.8M $42.4M
Dividends and buybacks $24.3M $19.7M $23.1M $27.4M $27.7M $29.6M $37.6M $36.2M $39.5M $66.3M
Balance sheet
Cash and short-term investments $102M $90.2M $123M $75.7M $105M $142M $147M $204M $289M $293M
Total debt $269M $218M $208M $58.6M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Finance lease liabilities $0.0M $0.0M $0.0M $1.5M $0.6M $0.1M $0.0M $0.0M $0.0M $0.0M
Current assets $441M $562M $664M $630M $566M $728M $873M $886M $957M $1.0B
Current liabilities $183M $262M $297M $304M $252M $337M $406M $372M $371M $360M
Inventory $174M $210M $248M $245M $220M $278M $373M $300M $301M $329M
Property and equipment, net $157M $196M $196M $199M $211M $214M $221M $268M $270M $286M
Total assets $1.2B $1.4B $1.5B $1.5B $1.4B $1.6B $1.6B $1.7B $1.7B $1.8B
Total liabilities $528M $616M $648M $550M $453M $538M $563M $558M $519M $500M
Shareholders' equity $654M $794M $825M $919M $944M $1.0B $1.0B $1.1B $1.2B $1.3B
Margins
Gross margin 37.6% 30.9% 29.5% 30.8% 28.7% 29.3% 29.9% 30.3% 29.4% 27.7%
Operating margin 11.1% 9.6% 9.0% 9.9% 2.8% 8.9% 9.5% 8.3% 9.6% 7.3%
EBITDA margin 15.4% 13.4% 12.4% 13.1% 6.7% 11.8% 11.6% 10.3% 12.0% 9.7%
Net margin 9.2% 4.7% 5.8% 7.4% 2.4% 6.3% 6.8% 7.1% 1.9% 6.6%
FCF margin 10.1% 4.6% 5.2% 8.7% 9.7% 3.7% 2.1% 7.5% 7.8% 5.0%
Returns
Return on capital 10.9% 7.2% 9.4% 12.3% 2.8% 10.6% 15.1% 14.0% 16.4% 11.1%
Return on capital employed 10.8% 11.6% 11.5% 12.8% 2.9% 11.1% 15.4% 12.8% 13.2% 9.1%
Return on equity 12.9% 8.5% 10.5% 12.9% 3.1% 9.4% 12.9% 12.7% 3.0% 9.2%
Return on assets 7.4% 4.8% 5.9% 7.6% 2.0% 6.3% 8.4% 8.4% 2.1% 6.5%
Growth
Revenue growth −12.7% 47.9% 13.0% 2.5% −21.2% 24.3% 32.4% −0.8% −5.3% −3.7%
Net income growth −32.0% −24.0% 37.5% 32.0% −74.4% 224.4% 42.9% 4.6% −74.4% 227.5%
EPS growth −31.5% −24.3% 36.9% 31.6% −74.5% 223.3% 41.9% 4.5% −74.5% 228.9%
FCF growth −11.5% −33.3% 28.0% 73.3% −11.8% −53.4% −22.2% 244.9% −1.5% −38.5%
Share count change −0.7% 0.2% 0.5% 0.5% 0.2% 0.3% 0.5% 0.2% 0.4% −0.5%
Financial health
Net debt / EBITDA 1.2x 0.7x 0.5x −0.1x −1.3x −0.8x −0.7x −1.0x −1.3x −1.7x
Debt / equity 0.4x 0.3x 0.3x 0.1x 0.0x 0.0x 0.0x 0.0x 0.0x 0.0x
Interest coverage 37.8x 17.4x 20.5x 31.2x 42.1x — — — — —
Current ratio 2.4x 2.2x 2.2x 2.1x 2.2x 2.2x 2.2x 2.4x 2.6x 2.8x
Quick ratio 1.5x 1.3x 1.4x 1.3x 1.4x 1.3x 1.2x 1.6x 1.8x 1.9x
Capital allocation
Capex / revenue 1.9% 1.8% 2.0% 2.0% 2.5% 2.6% 2.0% 3.2% 2.2% 2.8%
Stock comp / revenue 0.4% 0.3% 0.3% 0.4% 0.5% 0.3% 0.3% 0.4% 0.5% 0.5%
Payouts / FCF 27.3% 33.2% 30.4% 20.8% 23.8% 54.7% 89.3% 24.9% 27.6% 75.3%
Quality scores
Piotroski F-score 6.0 5.0 6.0 6.0 5.0 6.0 5.0 6.0 4.0 6.0
Altman Z'' 4.8 4.7 5.1 5.6 5.6 5.9 6.5 6.7 7.3 7.5
Accruals ratio −2.2% −1.6% −1.4% −3.4% −8.2% −0.0% 3.2% −4.1% −8.7% −1.2%

Source: SEC EDGAR XBRL filings (CIK 0001054905). Data updated October 21, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open